Pfizer, AstraZeneca and several other drugmakers in race to join weight loss drug market Ruchika Sharma23 Dec 2024 5:01 PM ISTPfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated to be worth about $150...
Tirzepatide versus Semaglutide- Surmount-5 trial reveals head-on comparison results Dr. Prem Aggarwal5 Dec 2024 12:00 PM ISTUS: Sharing the topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial, Eli Lilly and Company announced that participants...
GLP-1 receptor agonists also protect kidneys among patients with diabetes and obesity: Lancet Dr. Kamal Kant Kohli2 Dec 2024 8:15 AM ISTThe biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have...
Semaglutide associated with Nonarteritic Anterior Ischemic Optic Neuropathy: JAMA Dr Ishan Kataria28 Nov 2024 8:00 PM ISTNonarteritic anterior ischemic optic neuropathy (NAION) is the second most common form of optic neuropathy and a significant cause of blindness...
Semaglutide Improves Sperm Quality and Testosterone Levels in Obese Men with Type 2 Diabetes and Hypogonadism: Study Medha Baranwal21 Nov 2024 8:45 AM ISTSlovenia: A recent study published in Diabetes, Obesity and Metabolism has revealed that semaglutide, a medication primarily used to treat type 2...
Bariatric surgery imore cost effective than newer weight loss drugs alone, finds study Dr. Kamal Kant Kohli7 Nov 2024 9:45 PM ISTNewer weight loss drugs are cost effective in the long term only when combined with bariatric weight loss surgery, according to a study presented at...
Semaglutide 2.4 mg may significantly improve liver fibrosis and resolve MASH in ESSENCE trial Dr. Kamal Kant Kohli5 Nov 2024 9:30 AM ISTAccording to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver fibrosis and...
Which are High-impact clinical trials that may generate promising results for improving kidney health? Dr Kartikeya Kohli1 Nov 2024 8:00 PM ISTThe results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney...
Once-Weekly Semaglutide Cuts Heart Failure Risk in Diabetes and Kidney Disease: FLOW Trial Analysis Medha Baranwal29 Oct 2024 8:00 AM ISTUSA: In a significant advancement for cardiovascular care, the FLOW trial has demonstrated that semaglutide, a glucagon-like peptide-1 receptor...
Semaglutide may reduce risk of Alzheimer's disease in diabetes patients, suggests study Dr. Kamal Kant Kohli25 Oct 2024 8:00 PM ISTResearchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of...
Novo Nordisk's oral Semaglutide cuts cardiovascular risks by 14 percent, study finds MD Bureau23 Oct 2024 3:29 PM ISTNovo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the year.
Oral semaglutide cuts MACE risk by 14% in adults with type 2 diabetes: SOUL trial Dr. Kamal Kant Kohli22 Oct 2024 9:30 AM ISTAccording to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will present more detailed...
